Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies.
Initially used for the treatment of immunodeficiencies, intravenous immunoglobulin (IVIg) has increasingly been used as an immunomodulatory agent in immune thrombocytopenic purpura, autoimmune neuropathies, systemic lupus erythematosus, myasthenia gravis, Guillain-Barré syndrome, and Kawasaki disease. Although IVIg benefits have been reported in many autoimmune and systemic inflammatory diseases, its mechanisms of immunomodulation are not fully understood and probably involve Fc-dependent and/or F(ab')(2)-dependent mutually non-exclusive effects. These mechanisms of action of IVIg reflect the importance of natural antibodies in the maintenance of immune homeostasis. We discuss here the recent advances in the understanding of immunoregulatory effects of IVIg.
Sibéril
Sophie
S
Centre de Recherche des Cordeliers, Equipe 16- Immunopathology and therapeutic immunointervention, Université Pierre et Marie Curie Paris 6, UMR S 872, 15 rue de l'Ecole de Médicine, Paris, France.
Elluru
SriRamulu
S
Negi
Vir-Singh
VS
Ephrem
Amal
A
Misra
Namita
N
Delignat
Sandrine
S
Bayary
Jagadeesh
J
Lacroix-Desmazes
Sébastien
S
Kazatchkine
Michel D
MD
Kaveri
Srini V
SV
D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology*; D006706:Homeostasis / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000276:immunology / Q000627:therapeutic use; D007141:Immunoglobulin Fc Fragments / Q000276:immunology / Q000627:therapeutic use; D016756:Immunoglobulins, Intravenous / Q000276:immunology* / Q000627:therapeutic use; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy / Q000276:immunology; D007155:Immunologic Factors / Q000276:immunology* / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology
D007140:Immunoglobulin Fab Fragments; D007141:Immunoglobulin Fc Fragments; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors